Table 1.
Characteristics of studies included
| Study | n (cases) | Dose | Route | Form | Therapy Duration | Additional Treatment | MDA Mean ± SD Before | MDA Mean ± SD After | Biomarker | Country |
|---|---|---|---|---|---|---|---|---|---|---|
| Giardini et al., 1984 [28] | 19 | 300 mg/day 330 IU | IM | α-tocopherol acetate | 15 days | 19.53 ± 7.83 μg/ml | 0.46 ± 0.36 μg/ml | Erythrocyte MDA | Italy | |
| Taccone-Gallucci et al., 1985 [29] | 9 | 300 mg/day 330 IU | IM | α-tocopherol acetate | 15 days | 6.17 ± 1.3 μg/ml packed RBC | 0.63 ± 0.2 μg/ml packed RBC | RBC MDA | Italy | |
| Lubrano et al., 1986 [30] | 9 | 300 mg/day 330 IU | IM | α-tocopherol acetate | 15 days | 6.16 ± 1.29 μg/ml | 0.69 ± 0.13 μg/ml | Erythrocyte MDA | Italy | |
| Taccone-Gallucci et al., 1986 [31] | 10 | 300 mg/day 330 IU | IM | α-tocopherol acetate | 15 days | 16.92 ± 3.36 | 7.92 ± 5.80 T2 g/mg | PBMC MDA | Italy | |
| Taccone-Gallucci et al., 1989 [32] | 10 | 300 mg/day 330 IU | IM | α-tocopherol acetate | 15 days | 2.35 ± 1.46 | 0.5 ± 0.2 T2 μg/mg | Platelet MDA | Italy | |
| Hassan et al., 1995 [33] | 6 | 400 IU daily (268/449 mg) | Oral | unknown | 40 days | Vitamin A 4500 IU daily + Vitamin C 750 mg daily | 1.67 ± 0.37 | 0.51 ± 0.1 | RBC MDA | Iraq |
| Yukawa et al., 1995 [34] | 5 | 600 mg/day 900 IU | Oral | α-tocopherol | 2 weeks | 4.0 ± 0.6 nmol/ml | 3.3 ± 0.6 nmol/ml | MDA-LDL | Japan | |
| Cristol et al., 1997 [35] | 7 | 500 mg/day 750 IU | Oral | α-tocopherol | 6 months | EPO + Iron | 1.7 ± 0.1 nmol/ml | 1.2 ± 0.1 nmol/ml | Serum MDA | France |
| Inal et al., 1999 [36] | 36 | 300 mg/day 330/450 IU | Oral | unknown | 3 months | EPO | 4.05 ± 0.05 nmol/ml | 3.81 ± 0.09 nmol/ml | Plasma MDA | Turkey |
| Roob et al., 2000 [37] | 22 | 1080 mg 1200 IU | Oral | all-rac-α-tocopherylacetate | One dose | EPO + Iron | 1.20 + − 0.28 μmol/L | 1.09 ± 0.26 μmol/L | Plasma MDA | Austria |
| Bayes et al., 2001 [38] | 16 | 400 mg 3/week 440/600 IU | Oral | unknown | 3 months | EPO + Iron | 5.76 ± 1.83 μmol/L | 3.89 ± 1.14 μmol/L | Plasma MDA | Spain |
| Uzum et al., 2006 [39] | 19 | 300 mg/day 330/450 IU | Oral | unknown | 20 weeks | 2.77 ± 0.87 nmol/mL | 2.2 ± 0.767 nmol/mL | Plasma MDA | Turkey | |
| Youzbaki et al., 2010 [40] | 18 | 400 mg/day 600 IU | Oral | α-tocopherol | 3 weeks | 0.059 ± 0.027 μmol/L | 0.031 ± 0.021 μmol/L | Serum MDA | Iraq | |
| Ahmadia et al., 2013 [41] | 17 | 400 IU (268/449 mg) | Unknown | unknown | 2 months | 4.4 ± 1.6 μmol/L | 4.7 ± 1.2 μmol/L | Plasma MDA | Iran | |
| Ahmadib et al., 2013 [41] | 24 | 400 IU (268/449 mg) | Unknown | unknown | 2 months | 600 mg ALA | 4.9 ± 1.6 μmol/L | 4.5 ± 1.3 μmol/L | Plasma MDA | Iran |
| Daud et al., 2013 [42] | 41 | 220 mg/day (180 mg TT + 40 mg AT) | Oral | TT (⍺-TT, β-TT, 훾-TT, 훿-TT) + α-tocopherol | 16 weeks | 3.01 ± 4.65 μM | 2.89 ± 3.65 μM | Plasma MDA | USA | |
| Asemia et al., 2016 [43] | 30 | 268 mg/day 400 IU | Oral | α-tocopherol | 3 months | 3.2 ± 1.0 μmol/L | 3.7 ± 1.5 μmol/L | Plasma MDA | Iran | |
| Asemib et al., 2016 [43] | 30 | 268 mg/day 400 IU | Oral | α-tocopherol | 3 months | Omega 3 s | 3.5 ± 1.2 μmol/L | 3.4 ± 1.4 μmol/L | Plasma MDA | Iran |